Monocytes in the Peripheral Clearance of Amyloid-β and Alzheimer’s Disease
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Aging societies have high incidence rates of Alzheimer’s disease (AD). AD is diagnosed at later disease stages and has a poor prognosis, and effective drugs and treatments for AD are lacking. The molecular mechanism of AD is not clear, and current research focuses primarily on amyloid-β (Aβ) deposition and tau protein hyperphosphorylation. Aβ deposition is the most frequently hypothesized initiating factor of AD, and Aβ clearance during the pathogenesis of AD may be an optional strategy to suppress AD development. Monocytes play important roles in the peripheral clearance of Aβ. Therefore, the present review summarizes our current knowledge of the potential roles of infiltrating macrophages, circulating monocytes, and Kupffer cells in the peripheral clearance of Aβ in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Current understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083 · cited 1×
“Alzheimer’s disease (AD) is the most common neurodegenerative disorder; it leads to dementia and is responsible for approximately 80% of dementia cases [1].”
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
The cost of Alzheimer's disease in China and re‐estimation of costs worldwide
Jia, J., Wei, C., Chen, S., Li, F., Tang, Y., Qin, W., Zhao, L., Jin, H., Xu, H., Wang, F., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.12.006 · Cited by 752 · cited 1×
“Dementia also has a huge economic impact on various countries worldwide [3], and the total estimated worldwide cost of dementia was US$818 billion in 2016 [4].”
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
Saresella, M., La Rosa, F., Piancone, F., Zoppis, M., Marventano, I., Calabrese, E., Rainone, V., Nemni, R., Mancuso, R., & Clerici, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0088-1 · Cited by 489
Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477
Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology
Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C. A., Tan, J., Duman, R. S., & Flavell, R. A. (2008) · Nature Medicine · doi:10.1038/nm1781 · Cited by 422
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323
Tabet, N. (2006) · Age and Ageing · doi:10.1093/ageing/afl027 · Cited by 285 · cited 1×
“Some drugs, such as acetylcholinesterase inhibitors, directly inhibit cytokine release from microglia and monocytes and might exhibit anti-inflammatory effects in AD patients [48].”
Xiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277
Real-Time In Vivo Imaging Reveals the Ability of Monocytes to Clear Vascular Amyloid Beta
Michaud, J.-P., Bellavance, M.-A., Préfontaine, P., & Rivest, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.010 · Cited by 257
Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209
Tiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., Bagaglia, F., Kawarai, T., Zampolini, M., Orlacchio, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.003 · Cited by 162
Martin, E., Boucher, C., Fontaine, B., & Delarasse, C. (2017) · Aging Cell · doi:10.1111/acel.12522 · Cited by 156
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154
Koronyo, Y., Salumbides, B. C., Sheyn, J., Pelissier, L., Li, S., Ljubimov, V., Moyseyev, M., Daley, D., Fuchs, D.-T., Pham, M., et al. (2015) · Brain · doi:10.1093/brain/awv150 · Cited by 153
A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease
Naert, G., & Rivest, S. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt028 · Cited by 123
Guedes, J. R., Lao, T., Cardoso, A. L., & El Khoury, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00549 · Cited by 115
Varvel, N. H., Grathwohl, S. A., Degenhardt, K., Resch, C., Bosch, A., Jucker, M., & Neher, J. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150478 · Cited by 99
TREM1 facilitates microglial phagocytosis of amyloid beta
Jiang, T., Zhang, Y.-D., Gao, Q., Zhou, J.-S., Zhu, X.-C., Lu, H., Shi, J.-Q., Tan, L., Chen, Q., & Yu, J.-T. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1622-5 · Cited by 91
Pellicanò, M., Bulati, M., Buffa, S., Barbagallo, M., Di Prima, A., Misiano, G., Picone, P., Di Carlo, M., Nuzzo, D., Candore, G., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091714 · Cited by 86
Kokiko-Cochran, O., Ransohoff, L., Veenstra, M., Lee, S., Saber, M., Sikora, M., Teknipp, R., Xu, G., Bemiller, S., Wilson, G., et al. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.3970 · Cited by 49
Hochstrasser, T., Marksteiner, J., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., & Humpel, C. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000330468 · Cited by 31 · cited 1×
“The levels of CCL15, CXCL9 and p21 in peripheral blood monocytes were also decreased in AD patients [83].”
Cited by
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
Erythropoietin signaling in peripheral macrophages is required for systemic β‐amyloid clearance
Xu, L., Li, L., Pan, C., Song, J., Zhang, C., Wu, X., Hu, F., Liu, X., Zhang, Z., & Zhang, Z. (2022) · The EMBO Journal · doi:10.15252/embj.2022111038 · Cited by 29
Tian, C., Ao, Z., Cerneckis, J., Cai, H., Chen, L., Niu, H., Takayama, K., Kim, J., Shi, Y., Gu, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2708 · Cited by 24
“Given our observation that AD monocytes colocalized with A β debris, we next investigated whether these monocytes can effectively phagocytose A β and thus assist brain-resident cells in clearing AD-related debris ( 44 , 45 ).”
Metadata
- Authors
- Guo, H., Zhao, Z., Zhang, R., Chen, P., Zhang, X., Cheng, F., & Gou, X.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-04-03
- Volume
- 68
- Issue
- 4
- Pages
- 1391-1400
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2927951311
- Cited by
- 36
- References
- 27
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.